Biohaven Ltd. (NYSE:BHVN) is a top small-cap biotech stock according to analysts. William Blair maintains a bullish stance, citing the FDA’s Complete Response Letter for Vyglxia as a key driver for pipeline reprioritization. Biohaven reported Q3 2025 results with a net loss of $173.4 million, but saw improvement in non-GAAP net loss. The company closed the quarter with $263.8 million in cash balances. Biohaven focuses on therapies in immunology, neuroscience, and oncology.

Read more at Yahoo Finance: William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth